Gray bars = all closed cases (~200k/month, flat). Purple area = verbatim-containing cases (the searchable pool). Only verbatim records are searchable. The purple area is the denominator.
Percentage of all closed cases with a verbatim field. Each step is a poison center coming online. 6.7% to 90.0% in 16 months.
Bars = raw monthly cases (left axis). Line = rate per 10,000 verbatim records (right axis). If the line rises, the signal is real.
Early months had high per-verbatim rates when few centers reported. From mid-2025 onward (adoption >50%), the upward trend is reliable.
Normalized rate (line) is essentially flat. Raw bar growth is mostly adoption artifact.
32 total cases (including CagriSema combo product). Has its own product code (8618310). Coded under GLP-1 Agonists and Hypoglycemics: Other or Unknown. 7 misspellings found: cagliniide, cagrilinitide, cagrillintide, cargenlintide, cargrilintide, cagrisema, CagriSema.
Denominators from Dan's file 10 (ALL Calls) and file 11 (Verbatim Only), all GCs nationally. Substance counts from 71-GC dataset. March 2026† estimated from 5 days of data (x6.2). Rates use actual partial-month data (same 5/5 ratio in numerator and denominator).
| Month | All Cases | Verb Cases | Verb % | Retat | /10kV | 7-OH | /10kV | Medet | /10kV | Cagri | /10kV | Melan | /10kV |
|---|
Denominator: Total verbatim-containing closed cases per month across all GCs nationally, from "Case Log Counts Verbatim ONLY (11).xlsx" (1,913,218 total). This is the searchable pool: a substance can only be detected in a record that has a verbatim field.
Numerators: Substance-specific case counts from the 71-GC verbatim dataset (210,786 rows). Matched by regex on Verbatim and Product Code fields.
Rate: (substance cases / verbatim cases in month) x 10,000
March 2026 estimation: Dataset contains Mar 1-5 (5 days). Full-month estimates use factor of 31/5 = 6.2. Normalized rates are unaffected because both numerator and denominator cover the same 5 days.
Caveat: Numerator comes from 71 GCs; denominator covers all GCs. Absolute rates are conservative (denominator is broader). Trend direction is unaffected.
32 cases found across two product codes: Cagrilintide (8618310, 25 cases) and Semaglutide and Cagrilintide combo (8618352, 7 cases). Coded under two GCs: Hypoglycemics: Other or Unknown (0233000) and GLP-1 Agonists (0310100). 7 unique misspellings detected. 7 Moderate outcomes, 3 Minor, no deaths or Major effects. One case (Aug 2025) combined cagrilintide with retatrutide. Normalized rate is flat at ~0.1-0.3 per 10k verbatims, consistent with a low-volume approved pharmaceutical generating steady adverse event reports.